血清NY-ESO-1自身抗体在乳腺癌中的诊断价值
|
摘要
目的探讨血清癌-睾丸抗原NY-ESO-1自身抗体在乳腺癌中的诊断意义。方法采用酶联免疫吸附试验检测NY-ESO-1自身抗体在125例乳腺癌患者、33例乳腺良性肿瘤患者和116例健康体检者血清中的水平。结果乳腺癌患者组血清NY-ESO-1自身抗体的水平高于乳腺良性肿瘤和健康体检组,差异均有统计学意义(P﹤0.05)。当以0.226为诊断临界值时,NY-ESO-1自身抗体对乳腺癌的诊断曲线下面积为0.575(95%置信区间:0.695~0.816),敏感度为31.2%,特异度为96.6%。更重要的是,检测NY-ESO-1自身抗体能够区分乳腺癌和乳腺良性肿瘤,其诊断曲线下面积为0.629(95%置信区间:0.531~0.728),敏感度为31.2%,特异度为87.9%。结论血清NY-ESO-1自身抗体对乳腺癌具有诊断价值,是一种潜在的乳腺癌诊断血清标志物。
Objective To assess the diagnostic value of serum autoantibody against NY-ESO-1 in patients with breast cancer. Methods Levels of serum autoantibody against NY-ESO-1 were detected for 125 patients with breast cancer,33 patients with benign breast tumor and 116 healthy controls by using enzyme linked immunosorbent assay( ELISA). Results The serum levels of autoantibody against NY-ESO-1 were significantly higher in breast cancer than those in benign breast tumor and in healthy controls( P<0. 05). Based on a cut-off value of 0. 226,measurement of autoantibody against NY-ESO-1 provided an area under the curve of 0. 575( 95% confidence interval:0. 695—0. 816),a sensitivity of 31. 2% and a specificity of 96. 6%. Importantly,autoantibody against NY-ESO-1 could differentiate breast cancer from benign breast tumor with an area under the curve of 0. 629( 95% confidence interval: 0. 531—0. 728),a sensitivity of 31. 2% and a specificity of 87. 9%. Conclusion Autoantibody against NY-ESO-1 has diagnostic value for breast cancer,and has potential to be used as a diagnostic biomarker for breast cancer.
Objective To assess the diagnostic value of serum autoantibody against NY-ESO-1 in patients with breast cancer. Methods Levels of serum autoantibody against NY-ESO-1 were detected for 125 patients with breast cancer,33 patients with benign breast tumor and 116 healthy controls by using enzyme linked immunosorbent assay( ELISA). Results The serum levels of autoantibody against NY-ESO-1 were significantly higher in breast cancer than those in benign breast tumor and in healthy controls( P<0. 05). Based on a cut-off value of 0. 226,measurement of autoantibody against NY-ESO-1 provided an area under the curve of 0. 575( 95% confidence interval:0. 695—0. 816),a sensitivity of 31. 2% and a specificity of 96. 6%. Importantly,autoantibody against NY-ESO-1 could differentiate breast cancer from benign breast tumor with an area under the curve of 0. 629( 95% confidence interval: 0. 531—0. 728),a sensitivity of 31. 2% and a specificity of 87. 9%. Conclusion Autoantibody against NY-ESO-1 has diagnostic value for breast cancer,and has potential to be used as a diagnostic biomarker for breast cancer.
引文
[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2]Bleyer A,Welch HG.Effect of three decades of screening mammography on breast-cancer incidence[J].N Engl J Med,2012,367(21):1998-2005.
[3]Smetherman DH.Screening,imaging,and image-guided biopsy techniques for breast cancer[J].Surg Clin North Am,2013,93(2):309-327.
[4]Coolen A,Leunen K,Menten J,et al.False-negative tests in breast cancer management[J].Neth J Med,2011,69(7):324-329.
[5]Macdonald IK,Parsy-Kowalska CB,Chapman CJ.Autoantibodies:opportunities for early cancer detection[J].Trends Cancer,2017,3(3):198-213.
[6]Piura E,Piura B.Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma[J].J Oncol,2011,2011:982425.
[7]Robbins PF,Morgan RA,Feldman SA,et al.Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1[J].J Clin Oncol,2011,29(7):917-924.
[8]Jger E,Nagata Y,Gnjatic S,et al.Monitoring CD8 T cell responses to NY-ESO-1:correlation of humoral and cellular immune responses[J].Proc Natl Acad Sci USA,2000,97(9):4760-4765.
[9]Gnjatic S,Nishikawa H,Jungbluth AA,et al.NY-ESO-1:review of an immunogenic tumor antigen[J].Adv Cancer Res,2006,95:1-30.
[10]Yang J,Jiao S,Kang J,et al.Application of serum NYESO-1 antibody assay for early SCLC diagnosis[J].Int J Clin Exp Pathol,2015,8(11):14959-14964.
[11]Xu YW,Peng YH,Chen B,et al.Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma[J].Am J Gastroenterol,2014,109(1):36-45.
[12]Peng YH,Xu YW,Huang LS,et al.Autoantibody signatures combined with epstein-barr virus capsid antigen-Ig A as a biomarker panel for the detection of nasopharyngeal carcinoma[J].Cancer Prev Res(Phila),2015,8(8):729-736.
[13]Peng YH,Xu YW,Qiu SQ,et al.Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma[J].Oncol Lett,2014,8(3):1096-1102.
[14]Chapman C,Murray A,Chakrabarti J,et al.Autoantibodies in breast cancer:their use as an aid to early diagnosis[J].Ann Oncol,2007,18(5):868-873.
[15]Oshima Y,Shimada H,Yajima S,et al.NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer:screening in 1969 patients with various cancers[J].J Gastroenterol,2016,51(1):30-34.
[2]Bleyer A,Welch HG.Effect of three decades of screening mammography on breast-cancer incidence[J].N Engl J Med,2012,367(21):1998-2005.
[3]Smetherman DH.Screening,imaging,and image-guided biopsy techniques for breast cancer[J].Surg Clin North Am,2013,93(2):309-327.
[4]Coolen A,Leunen K,Menten J,et al.False-negative tests in breast cancer management[J].Neth J Med,2011,69(7):324-329.
[5]Macdonald IK,Parsy-Kowalska CB,Chapman CJ.Autoantibodies:opportunities for early cancer detection[J].Trends Cancer,2017,3(3):198-213.
[6]Piura E,Piura B.Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma[J].J Oncol,2011,2011:982425.
[7]Robbins PF,Morgan RA,Feldman SA,et al.Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1[J].J Clin Oncol,2011,29(7):917-924.
[8]Jger E,Nagata Y,Gnjatic S,et al.Monitoring CD8 T cell responses to NY-ESO-1:correlation of humoral and cellular immune responses[J].Proc Natl Acad Sci USA,2000,97(9):4760-4765.
[9]Gnjatic S,Nishikawa H,Jungbluth AA,et al.NY-ESO-1:review of an immunogenic tumor antigen[J].Adv Cancer Res,2006,95:1-30.
[10]Yang J,Jiao S,Kang J,et al.Application of serum NYESO-1 antibody assay for early SCLC diagnosis[J].Int J Clin Exp Pathol,2015,8(11):14959-14964.
[11]Xu YW,Peng YH,Chen B,et al.Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma[J].Am J Gastroenterol,2014,109(1):36-45.
[12]Peng YH,Xu YW,Huang LS,et al.Autoantibody signatures combined with epstein-barr virus capsid antigen-Ig A as a biomarker panel for the detection of nasopharyngeal carcinoma[J].Cancer Prev Res(Phila),2015,8(8):729-736.
[13]Peng YH,Xu YW,Qiu SQ,et al.Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma[J].Oncol Lett,2014,8(3):1096-1102.
[14]Chapman C,Murray A,Chakrabarti J,et al.Autoantibodies in breast cancer:their use as an aid to early diagnosis[J].Ann Oncol,2007,18(5):868-873.
[15]Oshima Y,Shimada H,Yajima S,et al.NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer:screening in 1969 patients with various cancers[J].J Gastroenterol,2016,51(1):30-34.